Showing 2131-2140 of 2526 results for "".
- Fight for Sight and Prevent Blindness Announce Recipient of the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-recipient-of-the-2020-joanne-angle-public-health-award/2478320/Fight for Sight and Prevent Blindness announced the recipient of the 2020 Joanne Angle Public Health Award as Angela R. Elam, MD, Clinical Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan. The $25,000 grant was awarded for Dr. Elam’s study, “Engag
- Aerie Pharmaceuticals Announces Interim 90-Day Topline Data From Its 6-Month Mercury 3 Clinical Trial in Europehttps://modernod.com/news/aerie-pharmaceuticals-announces-interim-90-day-topline-data-from-its-6-month-mercury-3-clinical-trial-in-europe/2478321/Aerie Pharmaceuticals announced successful interim 90-day topline data from its 6-month phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda to Ganfort, according to a company news release. Roclanda is marketed in the United States as Rocklatan (netarsudil and latanopro
- KKR to Acquire 1-800 Contacts from AEA Investorshttps://modernod.com/news/kkr-to-acquire-1-800-contacts-from-aea-investors/2478313/1-800 Contacts, the largest retailer of contact lenses in the US, announced a definitive agreement under which global investment firm KKR will acquire the company from AEA Investors. Financial terms of the transaction were not disclosed. “1-800 Contacts was founded 25 years ago to o
- Gyroscope Therapeutics Granted FDA Fast Track Designation for Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-granted-fda-fast-track-designation-for-investigational-gene-therapy-for-dry-amd/2478305/Gyroscope Therapeutics announced that the FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is i
- Retina Consultants of America Announces New Alliancehttps://modernod.com/news/retina-consultants-of-america-announces-new-alliance/2478304/VitreoRetinal Surgery PA, based in Minnesota, has joined Retina Consultants of America (RCA). This is the sixth retina specialty practice to join RCA as it continues to expand the company’s footprint across the United States, including California Retina Consultants, Retina Consultants of Housto
- Study Finds Novel Mechanism That May Confer Protection Against Glaucomahttps://modernod.com/news/study-finds-novel-mechanism-that-may-confer-protection-against-glaucoma/2478298/A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associa
- Oxford Says AstraZeneca Trial Illnesses May Not Be Linked to COVID-19 Vaccinehttps://modernod.com/news/oxford-says-astrazeneca-trial-illnesses-may-not-be-linked-to-covid-19-vaccine/2478290/Neurological symptoms developed by some volunteers in a trial testing AstraZeneca’s COVID-19 vaccine candidate AZD1222 either probably did not come about as a result of the vaccine, or there is not enough evidence to say one way or the other, according to the University of Oxford. The discl
- Medscape US and International Physicians’ COVID-19 Experience Report: Risk, Burnout, Lonelinesshttps://modernod.com/news/medscape-us-and-international-physicians-covid-19-experience-report-risk-burnout-loneliness/2478285/Physicians worldwide have put their physical and mental health at risk as they battled the coronavirus pandemic. In Medscape’s COVID-19 survey, almost 7,500 physicians from the United States, Brazil, France
- Recordati Rare Diseases Announces Availability of Cystadrops in the UShttps://modernod.com/news/recordati-rare-diseases-announces-availability-of-cystadrops-in-the-us/2478283/Recordati Rare Diseases announced that Cystadrops (cysteamine ophthalmic solution) 0.37% is now available for prescription and distribution across the United States. Cystadrops is a new, viscous eye drop solution that depletes cystine crystal deposits in the corne
- Aerie Pharmaceuticals Announces FDA Approval of its Athlone, Ireland Facility for Production of Rhopressahttps://modernod.com/news/aerie-pharmaceuticals-announces-fda-approval-of-its-athlone-ireland-facility-for-production-of-rhopressa/2478282/Aerie Pharmaceuticals announced that its sterile fill production facility in Athlone, Ireland has received approval from the FDA for production of Rhopressa (netarsudil ophthalmic solution) 0.02% for commercial distribution in the United States. This approval comes following the FDA review of the